CardiAQ Valve Technologies

First-in-class minimally invasive device for mitral heart valve replacement

CardiAQ Valve Technologies (CVT) has developed trans-apical and trans-femoral systems as minimally invasive alternatives to open heart surgery for mitral valve repair and replacement.

Early clinical data has shown that the CVT system improves heart pumping efficiency just as well as on open heart surgery, so improving outcome and recovery time.

CEO  Rob Michiels

Advent Contact  Shahzad Malik

Advent invested in CVT in 2011. CVT was acquired by Edwards Lifesciences in 2015 for a total consideration of $400m.
Exited Investments